Drug Trial Radar · NCT01665144
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,651
Actual
Start
Dec 20, 2012
Primary completion
Apr 29, 2016
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
Conditions
- Secondary Progressive Multiple Sclerosis
Interventions
BAF312Drug
0.25, 0.5, 1, and 2 mg film-coated tablets
PlaceboDrug
Film-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)Time frame: Baseline, every 3 month up to the maximum of approximately 3 years
Locations
290 sites in 31 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Berkeley, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Basalt, Colorado
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Englewood, Colorado
Novartis Investigative Site
Fairfield, Connecticut
Novartis Investigative Site
Delray Beach, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Ormond Beach, Florida
Novartis Investigative Site
Port Charlotte, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Vero Beach, Florida
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Evanston, Illinois
Novartis Investigative Site
Flossmoor, Illinois
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Plymouth, Minnesota
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Lebanon, New Hampshire
Novartis Investigative Site
Freehold, New Jersey
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
New York, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Patchogue, New York
Novartis Investigative Site
Stony Brook, New York
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Akron, Ohio
Showing 40 of 290 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.